April 7 (Reuters) - Gilead Sciences Inc GILD.O :
* FDA APPROVES TRODELVY®, THE FIRST TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER SHOWN TO IMPROVE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL
* TRODELVY SIGNIFICANTLY REDUCED RISK OF DEATH BY 49% COMPARED WITH SINGLE-AGENT CHEMOTHERAPY IN PHASE 3 ASCENT STUDY
* GILEAD SCIENCES - TRODELVY IS UNDER REGULATORY REVIEW IN THE EU AND IN THE UNITED KINGDOM, CANADA, SWITZERLAND AND AUSTRALIA AS PART OF PROJECT ORBIS
* GILEAD SCIENCES - TRODELVY U.S. PRESCRIBING INFORMATION HAS A BOXED WARNING FOR SEVERE OR LIFE-THREATENING NEUTROPENIA AND SEVERE DIARRHEA
* ADVERSE REACTIONS LEADING TO TREATMENT DISCONTINUATION OCCURRED IN 5% OF PATIENTS RECEIVING TRODELVY
* GILEAD SCIENCES - EUROPEAN MEDICINES AGENCY HAS ALSO VALIDATED A MARKETING AUTHORIZATION APPLICATION FOR TRODELVY IN THE EUROPEAN UNION